BSX Stock Analysis: Boston Scientific | NYSE
Medical Devices | NYSE, USA | Market Cap: 66.291m USD | 12M Return: -56.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 889M
EPS Trend: 99.5%
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Boston Scientific Corporation (NYSE: BSX) is a U.S.-based medical device manufacturer that develops, produces, and markets products for interventional medical specialties across two operating segments: MedSurg and Cardiovascular. Its portfolio spans gastrointestinal and urological devices, neurological systems for chronic pain and movement disorders, and a broad set of cardiology offerings including the WATCHMAN FLX left atrial appendage closure device, implantable cardiac monitors, defibrillators, and pacemakers. The company also serves peripheral vascular and oncology markets, distributing its products worldwide. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific has been listed on the NYSE since its 1992 IPO and is classified within the Health Care Equipment sub-industry.
The medical device sector is characterized by long product development cycles, regulatory oversight from agencies such as the U.S. Food and Drug Administration, and competition from other large diversified device makers including Medtronic, Abbott, and Johnson & Johnson. Boston Scientifics business model relies on a mix of recurring revenue from consumables and implantables, ongoing R&D investment to refresh its product pipeline, and global sales channels that allow it to serve hospitals, ambulatory surgery centers, and specialty physician practices across more than 100 countries.
- WATCHMAN FLX adoption drives structural heart segment revenue growth
- Axonics acquisition expands neuromodulation share against Medtronic competition
- China volume-based procurement pressures urology and endoscopy margins
| Net Income: 3.55b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: 19.95% < 20% (prev 12.97%; Δ 6.98% < -1%) |
| CFO/TA 0.10 > 3% & CFO 4.34b > Net Income 3.55b |
| Net Debt (9.63b) to EBITDA (5.49b): 1.75 < 3 |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.50b) vs 12m ago 0.13% < -2% |
| Gross Margin: 70.42% > 18% (prev 61.84%; Δ 8.58% > 0.5%) |
| Asset Turnover: 48.80% > 50% (prev 43.73%; Δ 5.07% > 0%) |
| Interest Coverage Ratio: 11.48 > 6 (EBIT TTM 4.10b / Interest Expense TTM 357.0m) |
| A: 0.09 (Total Current Assets 8.68b - Total Current Liabilities 4.57b) / Total Assets 44.4b |
| B: 0.16 (Retained Earnings 6.91b / Total Assets 44.4b) |
| C: 0.10 (EBIT TTM 4.10b / Avg Total Assets 42.2b) |
| D: 1.42 (Book Value of Equity 25.9b / Total Liabilities 18.2b) |
| Altman-Z'' = 3.26 = A |
| DSRI: 0.96 (Receivables 3.03b/2.69b, Revenue 20.6b/17.6b) |
| GMI: 0.88 (GM 61.84% / 70.42%) |
| AQI: 0.97 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.17 (Revenue 20.6b / 17.6b) |
| TATA: -0.02 (NI 3.55b - CFO 4.34b) / TA 44.4b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 44.77 with a total of 12,037,080 shares traded. Over the past week, the price has changed by -0.82%, over one month by -7.39%, over three months by -27.54% and over the past year by -56.89%.
Current recommended Stop Loss: 42.80 (which is 4.4% or 1.3 ATR below the current price).
Boston Scientific has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy BSX.
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 75 | 67.5% |
P/E Trailing = 18.6611
P/E Forward = 13.459
P/S = 3.2158
P/B = 2.5941
P/EG = 0.548
Revenue TTM = 20.6b USD
EBIT TTM = 4.10b USD
EBITDA TTM = 5.49b USD
Long Term Debt = 10.9b USD (from longTermDebt, last quarter)
Short Term Debt = 41.0m USD (from shortTermDebt, last quarter)
Debt = 11.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.0m
Net Debt = 9.63b USD (calculated: Debt 11.2b - CCE 1.52b)
Enterprise Value = 75.9b USD (66.3b + Debt 11.2b - CCE 1.52b)
Interest Coverage Ratio = 11.48 (Ebit TTM 4.10b / Interest Expense TTM 357.0m)
EV/FCF = 22.06x (Enterprise Value 75.9b / FCF TTM 3.44b)
FCF Yield = 4.53% (FCF TTM 3.44b / Enterprise Value 75.9b)
FCF Margin = 16.70% (FCF TTM 3.44b / Revenue TTM 20.6b)
Net Margin = 17.24% (Net Income TTM 3.55b / Revenue TTM 20.6b)
Gross Margin = 70.42% ((Revenue TTM 20.6b - Cost of Revenue TTM 6.10b) / Revenue TTM)
Gross Margin QoQ = 69.44% (prev 74.50%)
Tobins Q-Ratio = 1.71 (Enterprise Value 75.9b / Total Assets 44.4b)
Interest Expense / Debt = 3.20% (Interest Expense 357.0m / Debt 11.2b)
Taxrate = 4.92% (184.0m / 3.74b)
NOPAT = 3.90b (EBIT 4.10b * (1 - 4.92%))
Current Ratio = 1.90 (Total Current Assets 8.68b / Total Current Liabilities 4.57b)
Debt / Equity = 0.43 (Debt 11.2b / totalStockholderEquity, last quarter 25.9b)
Debt / EBITDA = 1.75 (Net Debt 9.63b / EBITDA 5.49b)
Debt / FCF = 2.80 (Net Debt 9.63b / FCF TTM 3.44b)
Total Stockholder Equity = 24.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.41% (Net Income 3.55b / Total Assets 44.4b)
RoE = 14.82% (Net Income TTM 3.55b / Total Stockholder Equity 24.0b)
RoCE = 11.76% (EBIT 4.10b / Capital Employed (Equity 24.0b + L.T.Debt 10.9b))
RoIC = 10.05% (NOPAT 3.90b / Invested Capital 38.8b)
WACC = 6.83% (E(66.3b)/V(77.4b) * Re(7.47%) + D(11.2b)/V(77.4b) * Rd(3.20%) * (1-Tc(0.05)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 0.54%
[DCF] Terminal Value 77.97% ; FCFF base≈3.21b ; Y1≈3.68b ; Y5≈5.42b
[DCF] Fair Price = 48.43 (EV 81.6b - Net Debt 9.63b = Equity 72.0b / Shares 1.49b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.55 | EPS CAGR: 21.81% | SUE: 0.53 | # QB: 0
Revenue Correlation: 99.68 | Revenue CAGR: 18.12% | SUE: 0.53 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.83 | Chg30d=-0.14% | Revisions=-77% | Analysts=23
EPS next Quarter (2026-09-30): EPS=0.84 | Chg30d=-0.31% | Revisions=-82% | Analysts=22
EPS current Year (2026-12-31): EPS=3.36 | Chg30d=-0.23% | Revisions=-84% | GrowthEPS=+9.9% | GrowthRev=+7.6%
EPS next Year (2027-12-31): EPS=3.72 | Chg30d=-0.47% | Revisions=-84% | GrowthEPS=+10.6% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: -95% (up=0, down=56)